Heavy! Hengrui's innovative drug toluene sulphate rematomamyloscopy sedatives were approved.

Guide: Injection of toluene sulfonate is a benzodiazepine class of drugs, is a new type of short-acting GABAa receptor agonistsrecently, Hengrui Pharmaceuticals received the approval of the State Drug Administration issued the "Drug Registration Approval", approved the company's 1 innovative drug injection with toluene sulfonate ryazole (commodity name: Repenin ®) for colonoscopy sedationcolonoscopy is an important means of diagnosis and treatment of digestive diseases, can clearly detect intestinal lesions, but also can be some intestinal lesions to be treated accordinglyColonoscopy needs to be carried out in the intestine, will produce strong stimulation of the intestine, most patients and colonoscopy with tension, anxiety and fear of psychology, the examination process may appear intestinal perforation, intestinal bleeding and other complications, a small number of patients can not tolerate and cooperate to complete colonoscopy operation, so that endoscopy physicians can not clearly diagnose and treat related diseasesColonoscopy sedation/anesthesia can effectively prevent discomfort during examination, eliminate the patient's fear and anxiety about colonoscopy, make the patient's comfort and compliance significantly improved when receiving colonoscopy, and create better conditions for endoscopy physiciansinjection with toluene sulphate is a benzodiazepine class of drugs, is a new type of short-acting GABAa receptor agonists, it is metabolized through the whole body plasma esterase, and metabolites are inactive, with rapid action, rapid awakening, small effects on the cardiovascular and respiratory system, and with sedatives and other advantagesIt was approved for sale in December 2019 for gastroscopy tests for sedationIn August 2019, colonoscopy sedatiative indications were declared and were included in the priority review process by the State Drug Administration due to its apparent therapeutic advantagesIn addition, the product also carried out clinical studies in the fields of general anesthesia, bronchoscopy and sedation, among which, general anaesthetic indications are in The Third Phase III clinical trial, bronchoscopy sedatives approved exemption phase I and Phase II clinical studies, direct lying iii clinical studiesinquiry, there is no similar products listed for sale at home and abroadPaion AG develops the benzodiazepine of Remaazole, which was approved by Mindy Pharmaceuticals in Japan in December 2018, filed for a new drug application in the U.Sin April 2019, and the U.SFDA accepted the application in June 2019Yichang Manfu (licensed by Paion AG) submitted a listing application to the State Drug Administration on November 15, 2018, in the current status of "in the process of review and approval"so far, the company has invested about RMB 79.21 million in research and development projects.